Literature DB >> 19484406

Cognitive effects of pegylated interferon in individuals with primary brain tumors.

Mercedes D Dickinson1, Christopher D Barr2, Merrill Hiscock3, Christina A Meyers4.   

Abstract

Cognitive changes associated with interferon treatment include impaired verbal memory, attention, processing speed, and executive functioning. Pegylated interferon is a relatively new, long-lasting form of interferon alpha, but data regarding its cognitive effects in brain tumor patients are limited. Participants in this study were 35 primary brain tumor patients who received pegylated interferon at tumor recurrence. A neuropsychological battery assessed verbal memory, executive functioning, attention, information processing speed, and language functioning. Individual growth curve analyses were used to estimate cognitive change throughout treatment with interferon. Results revealed performance declined on a task of psychomotor speed and upper extremity dexterity. Although decline in a few tests was found, its degree may have been reduced because individuals were tested after tumor recurrence where a substantial amount of cognitive change had already potentially occurred due to surgery, radiation therapy, and chemotherapy. Thus, participants may not have been starting at their baseline cognitive status and the potential neurotoxic effects of interferon may have been obscured by prior treatments. An alternative explanation, however, is that treatment with pegylated interferon did not produce further impairment and patients experienced stability in their cognitive functioning.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19484406     DOI: 10.1007/s11060-009-9920-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  21 in total

1.  Analysis of change: modeling individual growth.

Authors:  D J Francis; J M Fletcher; K K Stuebing; K C Davidson; N M Thompson
Journal:  J Consult Clin Psychol       Date:  1991-02

2.  Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma.

Authors:  R J Motzer; A Rakhit; M Ginsberg; K Rittweger; J Vuky; R Yu; S Fettner; L Hooftman
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

3.  The course of neurocognitive functioning in high-grade glioma patients.

Authors:  Ingeborg Bosma; Maaike J Vos; Jan J Heimans; Martin J B Taphoorn; Neil K Aaronson; Tjeerd J Postma; Henk M van der Ploeg; Martin Muller; W Peter Vandertop; Ben J Slotman; Martin Klein
Journal:  Neuro Oncol       Date:  2006-10-03       Impact factor: 12.300

4.  Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction.

Authors:  Charles L Raison; Andrey S Borisov; Sherry D Broadwell; Lucile Capuron; Bobbi J Woolwine; Ira M Jacobson; Charles B Nemeroff; Andrew H Miller
Journal:  J Clin Psychiatry       Date:  2005-01       Impact factor: 4.384

5.  Effect of interferon-alpha on cognitive functioning in patients with chronic hepatitis C.

Authors:  Robin C Hilsabeck; Tarek I Hassanein; Elizabeth A Ziegler; Meghan D Carlson; William Perry
Journal:  J Int Neuropsychol Soc       Date:  2005-01       Impact factor: 2.892

6.  Toxicity of adjuvant high-dose interferon-alpha-2b in patients with cutaneous melanoma at high risk of recurrence.

Authors:  J Schachter; B Brenner; E Fenig; J Yahav; G Marshak; A Sulkes; H Gutman
Journal:  Oncol Rep       Date:  1999 Nov-Dec       Impact factor: 3.906

Review 7.  Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C.

Authors:  C M Perry; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

8.  Cognitive dysfunction and depression during treatment with interferon-alpha and chemotherapy.

Authors:  Randall S Scheibel; Alan D Valentine; Susan O'Brien; Christina A Meyers
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2004       Impact factor: 2.198

9.  Reversible cognitive decline during high-dose alpha-interferon treatment.

Authors:  E Poutiainen; L Hokkanen; M L Niemi; M Färkkilä
Journal:  Pharmacol Biochem Behav       Date:  1994-04       Impact factor: 3.533

Review 10.  Neuropsychological dysfunction associated with cancer and cancer therapies: a conceptual review of an emerging target.

Authors:  J S Wefel; A E Kayl; C A Meyers
Journal:  Br J Cancer       Date:  2004-05-04       Impact factor: 7.640

View more
  2 in total

1.  Nano to micro delivery systems: targeting angiogenesis in brain tumors.

Authors:  Ariel Gilert; Marcelle Machluf
Journal:  J Angiogenes Res       Date:  2010-10-08

Review 2.  Cytokines: shifting the balance between glioma cells and tumor microenvironment after irradiation.

Authors:  Wei Zhou; Zheng Jiang; Xingang Li; Yangyang Xu; Zhenyu Shao
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-09       Impact factor: 4.553

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.